Depression represents a huge pharmaceutical market opportunity. There are approximately 350 million people worldwide with depression, and it is the leading cause of disability in the world. In the U.S., 9.1 percent of the population suffer from depression. Globally, fewer than half of depression sufferers receive treatment for their illness, and in some countries this […]
written on 11.03.2014